Format

Send to

Choose Destination
J Addict Med. 2017 May/Jun;11(3):197-204. doi: 10.1097/ADM.0000000000000297.

Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial.

Author information

1
Society of Alcoholism and Other Addictions, Vogur Hospital, Reykjavík, Iceland (VR, IH, TT, ME); Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Treatment Research Institute, Philadelphia, PA (GEW); and the National Institute on Drug Abuse, Rockville, MD (JK).

Abstract

OBJECTIVE:

Explore the efficacy of extended-release injectable naltrexone (XR-NTX) for preventing relapse to amphetamine use.

METHOD:

Clinical trial of 100 amphetamine-dependent, treatment-seeking patients who were randomized to 6 monthly 380 mg doses of XR-NTX or matching placebo before entering intensive outpatient after varying lengths of inpatient treatment in Reykjavik, Iceland. Weekly urine drug tests, retention, and standardized instruments assessed efficacy.

RESULTS:

Of 169 approached, 100 were randomized. Although amphetamine dependence was the main reason for seeking treatment, three-quarters or more of participants had 1 or more other substance dependencies. Of 51 randomized to XR-NTX, 20 received 4 or more injections; of 49 assigned to placebo, 26 received 4 or more injections. Of the planned 2400 weekly urine drug tests, 1247 were collected (52%); 4% of these were positive for amphetamine, 8% for benzodiazepine, 7% for marijuana, 1% for cocaine, and 1% for opioid. XR-NTX had no effect on amphetamine-positive tests, retention, or other outcomes. Those providing half or more of their tests attended more weeks of treatment than those providing less than half of their tests (m = 10.76 vs 3.31; t (92) = 5.91, P < 0.0001), and 92 participants provided at least 1 test.

CONCLUSIONS:

Adding XR-NTX to the usual combination of inpatient and intensive outpatient treatment did not reduce amphetamine use. The low prevalence of substance use among collected urine samples, and the association between collected samples and weeks in treatment, was consistent with other studies showing that staying in treatment is associated with better outcomes.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00154154.

PMID:
28379861
PMCID:
PMC5449233
DOI:
10.1097/ADM.0000000000000297
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center